Amarin borrows $100m to launch Vascepa but keeps alliance door open
This article was originally published in Scrip
Executive Summary
Amarin's stock price fell 18.4% to $9.75 per share in after-hours trading on 6 December after the company announced that it raised $100 million in non-equity financing from an investment fund managed by Pharmakon Advisors to support commercialization of its prescription fish oil pill Vascepa (icosapent ethyl) without a partner.
You may also be interested in...
Stockwatch: Those That Cannot Be Successful Raise Money
It struck me last week that that the quote attributed to George Bernard Shaw – "He who can, does. He who cannot, teaches." – can be modified to apply to an increasing cadre of small- and mid-capitalization life science companies. Success for these companies that resonates with investors is either to be acquired or to reach a valuation that is too big to be acquired. The opposite of success is not so easy to define since clinical, regulatory or commercial failure usually means coming back to investors for a bail out.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.